nodes	percent_of_prediction	percent_of_DWPC	metapath
Ciclesonide—NR3C1—urine—urinary bladder cancer	0.0185	0.127	CbGeAlD
Ciclesonide—CES1—prostate gland—urinary bladder cancer	0.0152	0.104	CbGeAlD
Ciclesonide—CES1—Fluoropyrimidine Activity—TYMP—urinary bladder cancer	0.0147	0.0495	CbGpPWpGaD
Ciclesonide—CYP3A4—urine—urinary bladder cancer	0.014	0.0963	CbGeAlD
Ciclesonide—CYP2D6—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.0139	0.0468	CbGpPWpGaD
Ciclesonide—CYP2D6—urine—urinary bladder cancer	0.0138	0.0948	CbGeAlD
Ciclesonide—CES1—Fluoropyrimidine Activity—RRM2—urinary bladder cancer	0.0115	0.0386	CbGpPWpGaD
Ciclesonide—SERPINA6—renal system—urinary bladder cancer	0.0104	0.0711	CbGeAlD
Ciclesonide—NR3C1—Endoderm Differentiation—BPTF—urinary bladder cancer	0.00946	0.0318	CbGpPWpGaD
Ciclesonide—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00912	0.0306	CbGpPWpGaD
Ciclesonide—CYP2D6—Miscellaneous substrates—CYP4B1—urinary bladder cancer	0.00908	0.0305	CbGpPWpGaD
Ciclesonide—CES1—female reproductive system—urinary bladder cancer	0.0083	0.057	CbGeAlD
Ciclesonide—SERPINA6—female reproductive system—urinary bladder cancer	0.00829	0.057	CbGeAlD
Ciclesonide—CYP2D6—Fatty acids—CYP4B1—urinary bladder cancer	0.00759	0.0255	CbGpPWpGaD
Ciclesonide—CES1—E2F transcription factor network—XRCC1—urinary bladder cancer	0.00677	0.0227	CbGpPWpGaD
Ciclesonide—CES1—NRF2 pathway—UGT2B7—urinary bladder cancer	0.00677	0.0227	CbGpPWpGaD
Ciclesonide—CES1—Fluoropyrimidine Activity—TYMS—urinary bladder cancer	0.00666	0.0224	CbGpPWpGaD
Ciclesonide—NR3C1—prostate gland—urinary bladder cancer	0.00665	0.0457	CbGeAlD
Ciclesonide—CYP2D6—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00644	0.0216	CbGpPWpGaD
Ciclesonide—NR3C1—Signaling events mediated by HDAC Class II—HDAC4—urinary bladder cancer	0.00626	0.021	CbGpPWpGaD
Ciclesonide—CES1—Fluoropyrimidine Activity—ERCC2—urinary bladder cancer	0.00619	0.0208	CbGpPWpGaD
Ciclesonide—CES1—E2F transcription factor network—RRM2—urinary bladder cancer	0.00609	0.0205	CbGpPWpGaD
Ciclesonide—CES1—Fluoropyrimidine Activity—MTHFR—urinary bladder cancer	0.00582	0.0195	CbGpPWpGaD
Ciclesonide—NR3C1—seminal vesicle—urinary bladder cancer	0.00563	0.0387	CbGeAlD
Ciclesonide—CYP2D6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00523	0.0176	CbGpPWpGaD
Ciclesonide—NR3C1—epithelium—urinary bladder cancer	0.00489	0.0336	CbGeAlD
Ciclesonide—CES1—lymph node—urinary bladder cancer	0.00486	0.0334	CbGeAlD
Ciclesonide—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00477	0.016	CbGpPWpGaD
Ciclesonide—NR3C1—smooth muscle tissue—urinary bladder cancer	0.00471	0.0324	CbGeAlD
Ciclesonide—NR3C1—renal system—urinary bladder cancer	0.00454	0.0312	CbGeAlD
Ciclesonide—NR3C1—urethra—urinary bladder cancer	0.00446	0.0306	CbGeAlD
Ciclesonide—NR3C1—Glucocorticoid receptor regulatory network—KRT5—urinary bladder cancer	0.00428	0.0144	CbGpPWpGaD
Ciclesonide—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00421	0.0141	CbGpPWpGaD
Ciclesonide—NR3C1—female reproductive system—urinary bladder cancer	0.00363	0.025	CbGeAlD
Ciclesonide—NR3C1—AP-1 transcription factor network—MT2A—urinary bladder cancer	0.00361	0.0121	CbGpPWpGaD
Ciclesonide—CES1—E2F transcription factor network—CCNE1—urinary bladder cancer	0.00359	0.0121	CbGpPWpGaD
Ciclesonide—CES1—E2F transcription factor network—TYMS—urinary bladder cancer	0.00353	0.0118	CbGpPWpGaD
Ciclesonide—CYP3A4—renal system—urinary bladder cancer	0.00343	0.0236	CbGeAlD
Ciclesonide—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00342	0.0115	CbGpPWpGaD
Ciclesonide—Alanine aminotransferase increased—Thiotepa—urinary bladder cancer	0.00341	0.00612	CcSEcCtD
Ciclesonide—CYP2D6—renal system—urinary bladder cancer	0.00338	0.0232	CbGeAlD
Ciclesonide—Oral candidiasis—Epirubicin—urinary bladder cancer	0.00337	0.00606	CcSEcCtD
Ciclesonide—Dyspnoea—Mitomycin—urinary bladder cancer	0.00337	0.00605	CcSEcCtD
Ciclesonide—Nasal congestion—Cisplatin—urinary bladder cancer	0.00332	0.00597	CcSEcCtD
Ciclesonide—NR3C1—vagina—urinary bladder cancer	0.00329	0.0226	CbGeAlD
Ciclesonide—Nausea—Valrubicin—urinary bladder cancer	0.00325	0.00585	CcSEcCtD
Ciclesonide—Fatigue—Mitomycin—urinary bladder cancer	0.00325	0.00585	CcSEcCtD
Ciclesonide—Swelling—Etoposide—urinary bladder cancer	0.00315	0.00565	CcSEcCtD
Ciclesonide—Face oedema—Gemcitabine—urinary bladder cancer	0.00314	0.00564	CcSEcCtD
Ciclesonide—Oral candidiasis—Doxorubicin—urinary bladder cancer	0.00312	0.00561	CcSEcCtD
Ciclesonide—NR3C1—FOXA2 and FOXA3 transcription factor networks—TFRC—urinary bladder cancer	0.00307	0.0103	CbGpPWpGaD
Ciclesonide—Weight increased—Thiotepa—urinary bladder cancer	0.00304	0.00546	CcSEcCtD
Ciclesonide—NR3C1—Nuclear Receptors—ESR2—urinary bladder cancer	0.00303	0.0102	CbGpPWpGaD
Ciclesonide—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.003	0.0101	CbGpPWpGaD
Ciclesonide—Pneumonia—Thiotepa—urinary bladder cancer	0.00299	0.00538	CcSEcCtD
Ciclesonide—Infestation NOS—Thiotepa—urinary bladder cancer	0.00298	0.00535	CcSEcCtD
Ciclesonide—Infestation—Thiotepa—urinary bladder cancer	0.00298	0.00535	CcSEcCtD
Ciclesonide—Face oedema—Cisplatin—urinary bladder cancer	0.00292	0.00525	CcSEcCtD
Ciclesonide—CES1—E2F transcription factor network—PLAU—urinary bladder cancer	0.00291	0.00977	CbGpPWpGaD
Ciclesonide—Conjunctivitis—Thiotepa—urinary bladder cancer	0.00289	0.0052	CcSEcCtD
Ciclesonide—Alanine aminotransferase increased—Gemcitabine—urinary bladder cancer	0.00287	0.00515	CcSEcCtD
Ciclesonide—Nasopharyngitis—Fluorouracil—urinary bladder cancer	0.00286	0.00513	CcSEcCtD
Ciclesonide—Influenza—Gemcitabine—urinary bladder cancer	0.00281	0.00505	CcSEcCtD
Ciclesonide—Epistaxis—Thiotepa—urinary bladder cancer	0.00281	0.00504	CcSEcCtD
Ciclesonide—CES1—E2F transcription factor network—ATM—urinary bladder cancer	0.00276	0.00928	CbGpPWpGaD
Ciclesonide—Bronchospasm—Gemcitabine—urinary bladder cancer	0.00276	0.00496	CcSEcCtD
Ciclesonide—CYP3A4—female reproductive system—urinary bladder cancer	0.00275	0.0189	CbGeAlD
Ciclesonide—Asthenia—Mitomycin—urinary bladder cancer	0.00271	0.00487	CcSEcCtD
Ciclesonide—Nasopharyngitis—Cisplatin—urinary bladder cancer	0.00271	0.00487	CcSEcCtD
Ciclesonide—CYP2D6—female reproductive system—urinary bladder cancer	0.0027	0.0186	CbGeAlD
Ciclesonide—Haemoglobin—Thiotepa—urinary bladder cancer	0.00269	0.00482	CcSEcCtD
Ciclesonide—Haemorrhage—Thiotepa—urinary bladder cancer	0.00267	0.0048	CcSEcCtD
Ciclesonide—CES1—NRF2 pathway—NQO1—urinary bladder cancer	0.00261	0.00878	CbGpPWpGaD
Ciclesonide—Dysphonia—Epirubicin—urinary bladder cancer	0.0026	0.00468	CcSEcCtD
Ciclesonide—NR3C1—Transcription factor regulation in adipogenesis—PPARG—urinary bladder cancer	0.0026	0.00873	CbGpPWpGaD
Ciclesonide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00258	0.00866	CbGpPWpGaD
Ciclesonide—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.00257	0.00461	CcSEcCtD
Ciclesonide—Pneumonia—Gemcitabine—urinary bladder cancer	0.00252	0.00452	CcSEcCtD
Ciclesonide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.0025	0.00841	CbGpPWpGaD
Ciclesonide—Dizziness—Mitomycin—urinary bladder cancer	0.0025	0.00448	CcSEcCtD
Ciclesonide—Pneumonia—Fluorouracil—urinary bladder cancer	0.00248	0.00445	CcSEcCtD
Ciclesonide—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00247	0.0083	CbGpPWpGaD
Ciclesonide—Infestation—Fluorouracil—urinary bladder cancer	0.00246	0.00442	CcSEcCtD
Ciclesonide—Infestation NOS—Fluorouracil—urinary bladder cancer	0.00246	0.00442	CcSEcCtD
Ciclesonide—Alanine aminotransferase increased—Etoposide—urinary bladder cancer	0.00245	0.0044	CcSEcCtD
Ciclesonide—Ulcer—Methotrexate—urinary bladder cancer	0.00242	0.00435	CcSEcCtD
Ciclesonide—Immune system disorder—Thiotepa—urinary bladder cancer	0.00241	0.00434	CcSEcCtD
Ciclesonide—Dysphonia—Doxorubicin—urinary bladder cancer	0.00241	0.00433	CcSEcCtD
Ciclesonide—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.00241	0.00433	CcSEcCtD
Ciclesonide—CES1—E2F transcription factor network—CREBBP—urinary bladder cancer	0.0024	0.00806	CbGpPWpGaD
Ciclesonide—NR3C1—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.0024	0.00805	CbGpPWpGaD
Ciclesonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOR1—urinary bladder cancer	0.00239	0.00804	CbGpPWpGaD
Ciclesonide—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.00239	0.0043	CcSEcCtD
Ciclesonide—Conjunctivitis—Fluorouracil—urinary bladder cancer	0.00239	0.0043	CcSEcCtD
Ciclesonide—CES1—E2F transcription factor network—RB1—urinary bladder cancer	0.00239	0.00803	CbGpPWpGaD
Ciclesonide—Rash—Mitomycin—urinary bladder cancer	0.00238	0.00428	CcSEcCtD
Ciclesonide—Dermatitis—Mitomycin—urinary bladder cancer	0.00238	0.00427	CcSEcCtD
Ciclesonide—Headache—Mitomycin—urinary bladder cancer	0.00236	0.00425	CcSEcCtD
Ciclesonide—Bronchospasm—Etoposide—urinary bladder cancer	0.00236	0.00424	CcSEcCtD
Ciclesonide—Epistaxis—Fluorouracil—urinary bladder cancer	0.00232	0.00417	CcSEcCtD
Ciclesonide—Sinusitis—Fluorouracil—urinary bladder cancer	0.00231	0.00415	CcSEcCtD
Ciclesonide—Conjunctivitis—Cisplatin—urinary bladder cancer	0.00227	0.00408	CcSEcCtD
Ciclesonide—Ulcer—Epirubicin—urinary bladder cancer	0.00227	0.00407	CcSEcCtD
Ciclesonide—Haemoglobin—Gemcitabine—urinary bladder cancer	0.00226	0.00406	CcSEcCtD
Ciclesonide—Rhinitis—Gemcitabine—urinary bladder cancer	0.00225	0.00405	CcSEcCtD
Ciclesonide—Back pain—Thiotepa—urinary bladder cancer	0.00225	0.00404	CcSEcCtD
Ciclesonide—Haemorrhage—Gemcitabine—urinary bladder cancer	0.00225	0.00404	CcSEcCtD
Ciclesonide—Nausea—Mitomycin—urinary bladder cancer	0.00224	0.00403	CcSEcCtD
Ciclesonide—Pharyngitis—Gemcitabine—urinary bladder cancer	0.00223	0.00401	CcSEcCtD
Ciclesonide—Haemoglobin—Fluorouracil—urinary bladder cancer	0.00222	0.00399	CcSEcCtD
Ciclesonide—Rhinitis—Fluorouracil—urinary bladder cancer	0.00222	0.00398	CcSEcCtD
Ciclesonide—Haemorrhage—Fluorouracil—urinary bladder cancer	0.00221	0.00397	CcSEcCtD
Ciclesonide—CES1—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.00221	0.00742	CbGpPWpGaD
Ciclesonide—Pharyngitis—Fluorouracil—urinary bladder cancer	0.00219	0.00394	CcSEcCtD
Ciclesonide—CES1—NRF2 pathway—GSTP1—urinary bladder cancer	0.00218	0.00732	CbGpPWpGaD
Ciclesonide—Pneumonia—Etoposide—urinary bladder cancer	0.00215	0.00386	CcSEcCtD
Ciclesonide—Infestation NOS—Etoposide—urinary bladder cancer	0.00214	0.00384	CcSEcCtD
Ciclesonide—Infestation—Etoposide—urinary bladder cancer	0.00214	0.00384	CcSEcCtD
Ciclesonide—NR3C1—lymph node—urinary bladder cancer	0.00212	0.0146	CbGeAlD
Ciclesonide—CES1—E2F transcription factor network—CDKN2A—urinary bladder cancer	0.0021	0.00706	CbGpPWpGaD
Ciclesonide—Ulcer—Doxorubicin—urinary bladder cancer	0.0021	0.00377	CcSEcCtD
Ciclesonide—Candida infection—Epirubicin—urinary bladder cancer	0.00205	0.00367	CcSEcCtD
Ciclesonide—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00203	0.00682	CbGpPWpGaD
Ciclesonide—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00203	0.00365	CcSEcCtD
Ciclesonide—Cough—Thiotepa—urinary bladder cancer	0.00203	0.00365	CcSEcCtD
Ciclesonide—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.00203	0.00364	CcSEcCtD
Ciclesonide—Hypertension—Thiotepa—urinary bladder cancer	0.00201	0.00361	CcSEcCtD
Ciclesonide—CES1—NRF2 pathway—GSTM1—urinary bladder cancer	0.002	0.00673	CbGpPWpGaD
Ciclesonide—Arthralgia—Thiotepa—urinary bladder cancer	0.00198	0.00356	CcSEcCtD
Ciclesonide—Diabetes mellitus—Methotrexate—urinary bladder cancer	0.00191	0.00343	CcSEcCtD
Ciclesonide—Back pain—Gemcitabine—urinary bladder cancer	0.00189	0.0034	CcSEcCtD
Ciclesonide—Candida infection—Doxorubicin—urinary bladder cancer	0.00189	0.0034	CcSEcCtD
Ciclesonide—Immune system disorder—Cisplatin—urinary bladder cancer	0.00189	0.0034	CcSEcCtD
Ciclesonide—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.00189	0.00339	CcSEcCtD
Ciclesonide—Infection—Thiotepa—urinary bladder cancer	0.00189	0.00339	CcSEcCtD
Ciclesonide—NR3C1—Signaling events mediated by HDAC Class II—ESR1—urinary bladder cancer	0.00184	0.00618	CbGpPWpGaD
Ciclesonide—NR3C1—Nuclear Receptors—ESR1—urinary bladder cancer	0.00184	0.00618	CbGpPWpGaD
Ciclesonide—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.00184	0.00618	CbGpPWpGaD
Ciclesonide—Diabetes mellitus—Epirubicin—urinary bladder cancer	0.00179	0.00321	CcSEcCtD
Ciclesonide—NR3C1—Circadian Clock—NCOR1—urinary bladder cancer	0.00174	0.00585	CbGpPWpGaD
Ciclesonide—Immune system disorder—Etoposide—urinary bladder cancer	0.00173	0.00311	CcSEcCtD
Ciclesonide—Mediastinal disorder—Etoposide—urinary bladder cancer	0.00173	0.00311	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00173	0.00311	CcSEcCtD
Ciclesonide—CES1—E2F transcription factor network—CDKN1A—urinary bladder cancer	0.00172	0.00577	CbGpPWpGaD
Ciclesonide—Cough—Gemcitabine—urinary bladder cancer	0.00171	0.00307	CcSEcCtD
Ciclesonide—Hypertension—Gemcitabine—urinary bladder cancer	0.00169	0.00303	CcSEcCtD
Ciclesonide—NR3C1—Nuclear Receptors—PPARG—urinary bladder cancer	0.00168	0.00564	CbGpPWpGaD
Ciclesonide—Dyspepsia—Thiotepa—urinary bladder cancer	0.00167	0.003	CcSEcCtD
Ciclesonide—Chest pain—Gemcitabine—urinary bladder cancer	0.00167	0.00299	CcSEcCtD
Ciclesonide—Arthralgia—Gemcitabine—urinary bladder cancer	0.00167	0.00299	CcSEcCtD
Ciclesonide—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.00165	0.00297	CcSEcCtD
Ciclesonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—urinary bladder cancer	0.00165	0.00553	CbGpPWpGaD
Ciclesonide—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00164	0.00294	CcSEcCtD
Ciclesonide—Chest pain—Fluorouracil—urinary bladder cancer	0.00164	0.00294	CcSEcCtD
Ciclesonide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00164	0.0055	CbGpPWpGaD
Ciclesonide—Fatigue—Thiotepa—urinary bladder cancer	0.00164	0.00294	CcSEcCtD
Ciclesonide—Dysgeusia—Etoposide—urinary bladder cancer	0.00164	0.00294	CcSEcCtD
Ciclesonide—CES1—E2F transcription factor network—EP300—urinary bladder cancer	0.00164	0.00549	CbGpPWpGaD
Ciclesonide—Back pain—Etoposide—urinary bladder cancer	0.00162	0.0029	CcSEcCtD
Ciclesonide—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00162	0.00543	CbGpPWpGaD
Ciclesonide—Infection—Gemcitabine—urinary bladder cancer	0.00159	0.00285	CcSEcCtD
Ciclesonide—Infection—Fluorouracil—urinary bladder cancer	0.00156	0.0028	CcSEcCtD
Ciclesonide—Pain in extremity—Epirubicin—urinary bladder cancer	0.00156	0.00279	CcSEcCtD
Ciclesonide—Urticaria—Thiotepa—urinary bladder cancer	0.00151	0.00271	CcSEcCtD
Ciclesonide—Face oedema—Epirubicin—urinary bladder cancer	0.0015	0.0027	CcSEcCtD
Ciclesonide—Infection—Cisplatin—urinary bladder cancer	0.00148	0.00266	CcSEcCtD
Ciclesonide—Cough—Etoposide—urinary bladder cancer	0.00146	0.00262	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00145	0.00261	CcSEcCtD
Ciclesonide—NR3C1—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.00145	0.00488	CbGpPWpGaD
Ciclesonide—Hypertension—Etoposide—urinary bladder cancer	0.00144	0.00259	CcSEcCtD
Ciclesonide—Pain in extremity—Doxorubicin—urinary bladder cancer	0.00144	0.00259	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00143	0.00257	CcSEcCtD
Ciclesonide—CES1—E2F transcription factor network—MYC—urinary bladder cancer	0.00142	0.00478	CbGpPWpGaD
Ciclesonide—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00142	0.00256	CcSEcCtD
Ciclesonide—Chest pain—Etoposide—urinary bladder cancer	0.00142	0.00256	CcSEcCtD
Ciclesonide—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00141	0.00473	CbGpPWpGaD
Ciclesonide—Dyspnoea—Fluorouracil—urinary bladder cancer	0.0014	0.00251	CcSEcCtD
Ciclesonide—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.00139	0.0025	CcSEcCtD
Ciclesonide—Face oedema—Doxorubicin—urinary bladder cancer	0.00139	0.0025	CcSEcCtD
Ciclesonide—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00138	0.00248	CcSEcCtD
Ciclesonide—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.00138	0.00464	CbGpPWpGaD
Ciclesonide—NR3C1—Transcription factor regulation in adipogenesis—TNF—urinary bladder cancer	0.00138	0.00464	CbGpPWpGaD
Ciclesonide—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00138	0.00248	CcSEcCtD
Ciclesonide—Fatigue—Gemcitabine—urinary bladder cancer	0.00138	0.00247	CcSEcCtD
Ciclesonide—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.00137	0.00246	CcSEcCtD
Ciclesonide—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00136	0.00458	CbGpPWpGaD
Ciclesonide—Asthenia—Thiotepa—urinary bladder cancer	0.00136	0.00245	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00136	0.00244	CcSEcCtD
Ciclesonide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00136	0.00244	CcSEcCtD
Ciclesonide—Infection—Etoposide—urinary bladder cancer	0.00135	0.00243	CcSEcCtD
Ciclesonide—Influenza—Epirubicin—urinary bladder cancer	0.00134	0.00241	CcSEcCtD
Ciclesonide—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.00133	0.0024	CcSEcCtD
Ciclesonide—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00133	0.00446	CbGpPWpGaD
Ciclesonide—Dyspnoea—Cisplatin—urinary bladder cancer	0.00133	0.00238	CcSEcCtD
Ciclesonide—NR3C1—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.00133	0.00446	CbGpPWpGaD
Ciclesonide—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00132	0.00444	CbGpPWpGaD
Ciclesonide—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.00131	0.0044	CbGpPWpGaD
Ciclesonide—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.00131	0.0044	CbGpPWpGaD
Ciclesonide—Bronchitis—Epirubicin—urinary bladder cancer	0.00129	0.00232	CcSEcCtD
Ciclesonide—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00129	0.00434	CbGpPWpGaD
Ciclesonide—Pneumonia—Methotrexate—urinary bladder cancer	0.00129	0.00231	CcSEcCtD
Ciclesonide—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.00129	0.00231	CcSEcCtD
Ciclesonide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00129	0.00231	CcSEcCtD
Ciclesonide—Infestation NOS—Methotrexate—urinary bladder cancer	0.00128	0.0023	CcSEcCtD
Ciclesonide—Infestation—Methotrexate—urinary bladder cancer	0.00128	0.0023	CcSEcCtD
Ciclesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOR1—urinary bladder cancer	0.00128	0.00429	CbGpPWpGaD
Ciclesonide—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.00127	0.00228	CcSEcCtD
Ciclesonide—Dizziness—Thiotepa—urinary bladder cancer	0.00126	0.00226	CcSEcCtD
Ciclesonide—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.00125	0.00224	CcSEcCtD
Ciclesonide—Urticaria—Fluorouracil—urinary bladder cancer	0.00125	0.00224	CcSEcCtD
Ciclesonide—Conjunctivitis—Methotrexate—urinary bladder cancer	0.00124	0.00224	CcSEcCtD
Ciclesonide—Influenza—Doxorubicin—urinary bladder cancer	0.00124	0.00223	CcSEcCtD
Ciclesonide—NR3C1—Regulation of Androgen receptor activity—CREBBP—urinary bladder cancer	0.00124	0.00415	CbGpPWpGaD
Ciclesonide—Weight increased—Epirubicin—urinary bladder cancer	0.00122	0.0022	CcSEcCtD
Ciclesonide—Dyspnoea—Etoposide—urinary bladder cancer	0.00122	0.00218	CcSEcCtD
Ciclesonide—Epistaxis—Methotrexate—urinary bladder cancer	0.00121	0.00217	CcSEcCtD
Ciclesonide—Pneumonia—Epirubicin—urinary bladder cancer	0.00121	0.00217	CcSEcCtD
Ciclesonide—NR3C1—Circadian Clock—CREBBP—urinary bladder cancer	0.0012	0.00403	CbGpPWpGaD
Ciclesonide—NR3C1—AP-1 transcription factor network—PLAU—urinary bladder cancer	0.0012	0.00403	CbGpPWpGaD
Ciclesonide—Infestation—Epirubicin—urinary bladder cancer	0.0012	0.00215	CcSEcCtD
Ciclesonide—Infestation NOS—Epirubicin—urinary bladder cancer	0.0012	0.00215	CcSEcCtD
Ciclesonide—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.0012	0.00402	CbGpPWpGaD
Ciclesonide—Rash—Thiotepa—urinary bladder cancer	0.0012	0.00215	CcSEcCtD
Ciclesonide—Bronchitis—Doxorubicin—urinary bladder cancer	0.0012	0.00215	CcSEcCtD
Ciclesonide—Dermatitis—Thiotepa—urinary bladder cancer	0.0012	0.00215	CcSEcCtD
Ciclesonide—Headache—Thiotepa—urinary bladder cancer	0.00119	0.00214	CcSEcCtD
Ciclesonide—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00118	0.00397	CbGpPWpGaD
Ciclesonide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00118	0.00212	CcSEcCtD
Ciclesonide—Fatigue—Etoposide—urinary bladder cancer	0.00118	0.00211	CcSEcCtD
Ciclesonide—Conjunctivitis—Epirubicin—urinary bladder cancer	0.00117	0.00209	CcSEcCtD
Ciclesonide—Urinary tract infection—Epirubicin—urinary bladder cancer	0.00117	0.00209	CcSEcCtD
Ciclesonide—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.00116	0.00208	CcSEcCtD
Ciclesonide—Haemoglobin—Methotrexate—urinary bladder cancer	0.00116	0.00208	CcSEcCtD
Ciclesonide—Haemorrhage—Methotrexate—urinary bladder cancer	0.00115	0.00207	CcSEcCtD
Ciclesonide—Asthenia—Gemcitabine—urinary bladder cancer	0.00115	0.00206	CcSEcCtD
Ciclesonide—Pharyngitis—Methotrexate—urinary bladder cancer	0.00114	0.00205	CcSEcCtD
Ciclesonide—Weight increased—Doxorubicin—urinary bladder cancer	0.00113	0.00203	CcSEcCtD
Ciclesonide—Epistaxis—Epirubicin—urinary bladder cancer	0.00113	0.00203	CcSEcCtD
Ciclesonide—NR3C1—AP-1 transcription factor network—ESR1—urinary bladder cancer	0.00113	0.00379	CbGpPWpGaD
Ciclesonide—Nausea—Thiotepa—urinary bladder cancer	0.00113	0.00203	CcSEcCtD
Ciclesonide—Sinusitis—Epirubicin—urinary bladder cancer	0.00112	0.00202	CcSEcCtD
Ciclesonide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—urinary bladder cancer	0.00112	0.00377	CbGpPWpGaD
Ciclesonide—Pneumonia—Doxorubicin—urinary bladder cancer	0.00112	0.002	CcSEcCtD
Ciclesonide—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00111	0.00199	CcSEcCtD
Ciclesonide—Infestation—Doxorubicin—urinary bladder cancer	0.00111	0.00199	CcSEcCtD
Ciclesonide—Urticaria—Etoposide—urinary bladder cancer	0.00108	0.00195	CcSEcCtD
Ciclesonide—Haemoglobin—Epirubicin—urinary bladder cancer	0.00108	0.00194	CcSEcCtD
Ciclesonide—Rhinitis—Epirubicin—urinary bladder cancer	0.00108	0.00194	CcSEcCtD
Ciclesonide—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.00108	0.00362	CbGpPWpGaD
Ciclesonide—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.00108	0.00194	CcSEcCtD
Ciclesonide—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00108	0.00194	CcSEcCtD
Ciclesonide—Haemorrhage—Epirubicin—urinary bladder cancer	0.00108	0.00193	CcSEcCtD
Ciclesonide—Asthenia—Cisplatin—urinary bladder cancer	0.00107	0.00192	CcSEcCtD
Ciclesonide—Pharyngitis—Epirubicin—urinary bladder cancer	0.00107	0.00192	CcSEcCtD
Ciclesonide—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00106	0.00357	CbGpPWpGaD
Ciclesonide—Epistaxis—Doxorubicin—urinary bladder cancer	0.00105	0.00188	CcSEcCtD
Ciclesonide—Sinusitis—Doxorubicin—urinary bladder cancer	0.00104	0.00187	CcSEcCtD
Ciclesonide—Immune system disorder—Methotrexate—urinary bladder cancer	0.00104	0.00187	CcSEcCtD
Ciclesonide—Dizziness—Fluorouracil—urinary bladder cancer	0.00104	0.00187	CcSEcCtD
Ciclesonide—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00104	0.00186	CcSEcCtD
Ciclesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—urinary bladder cancer	0.00101	0.00339	CbGpPWpGaD
Ciclesonide—Rash—Gemcitabine—urinary bladder cancer	0.00101	0.00181	CcSEcCtD
Ciclesonide—Dermatitis—Gemcitabine—urinary bladder cancer	0.00101	0.00181	CcSEcCtD
Ciclesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—urinary bladder cancer	0.001	0.00337	CbGpPWpGaD
Ciclesonide—Haemoglobin—Doxorubicin—urinary bladder cancer	0.001	0.0018	CcSEcCtD
Ciclesonide—Headache—Gemcitabine—urinary bladder cancer	0.001	0.0018	CcSEcCtD
Ciclesonide—Rhinitis—Doxorubicin—urinary bladder cancer	0.000998	0.00179	CcSEcCtD
Ciclesonide—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000996	0.00179	CcSEcCtD
Ciclesonide—Rash—Fluorouracil—urinary bladder cancer	0.00099	0.00178	CcSEcCtD
Ciclesonide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000989	0.00178	CcSEcCtD
Ciclesonide—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000988	0.00178	CcSEcCtD
Ciclesonide—Headache—Fluorouracil—urinary bladder cancer	0.000984	0.00177	CcSEcCtD
Ciclesonide—NR3C1—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.00098	0.00329	CbGpPWpGaD
Ciclesonide—Dysgeusia—Methotrexate—urinary bladder cancer	0.00098	0.00176	CcSEcCtD
Ciclesonide—Asthenia—Etoposide—urinary bladder cancer	0.000978	0.00176	CcSEcCtD
Ciclesonide—Immune system disorder—Epirubicin—urinary bladder cancer	0.000972	0.00175	CcSEcCtD
Ciclesonide—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00097	0.00174	CcSEcCtD
Ciclesonide—Back pain—Methotrexate—urinary bladder cancer	0.000968	0.00174	CcSEcCtD
Ciclesonide—Nausea—Gemcitabine—urinary bladder cancer	0.000949	0.0017	CcSEcCtD
Ciclesonide—Rash—Cisplatin—urinary bladder cancer	0.000939	0.00169	CcSEcCtD
Ciclesonide—Dermatitis—Cisplatin—urinary bladder cancer	0.000938	0.00168	CcSEcCtD
Ciclesonide—Nausea—Fluorouracil—urinary bladder cancer	0.000933	0.00168	CcSEcCtD
Ciclesonide—Dysgeusia—Epirubicin—urinary bladder cancer	0.000917	0.00165	CcSEcCtD
Ciclesonide—Back pain—Epirubicin—urinary bladder cancer	0.000906	0.00163	CcSEcCtD
Ciclesonide—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000903	0.00303	CbGpPWpGaD
Ciclesonide—Dizziness—Etoposide—urinary bladder cancer	0.000902	0.00162	CcSEcCtD
Ciclesonide—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000899	0.00162	CcSEcCtD
Ciclesonide—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000897	0.00161	CcSEcCtD
Ciclesonide—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000891	0.00299	CbGpPWpGaD
Ciclesonide—Nausea—Cisplatin—urinary bladder cancer	0.000884	0.00159	CcSEcCtD
Ciclesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	0.00088	0.00296	CbGpPWpGaD
Ciclesonide—NR3C1—Adipogenesis—NCOR1—urinary bladder cancer	0.000876	0.00294	CbGpPWpGaD
Ciclesonide—Cough—Methotrexate—urinary bladder cancer	0.000873	0.00157	CcSEcCtD
Ciclesonide—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—urinary bladder cancer	0.000872	0.00293	CbGpPWpGaD
Ciclesonide—NR3C1—AP-1 transcription factor network—CDKN2A—urinary bladder cancer	0.000867	0.00291	CbGpPWpGaD
Ciclesonide—Rash—Etoposide—urinary bladder cancer	0.00086	0.00154	CcSEcCtD
Ciclesonide—Dermatitis—Etoposide—urinary bladder cancer	0.000859	0.00154	CcSEcCtD
Ciclesonide—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000856	0.00288	CbGpPWpGaD
Ciclesonide—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000856	0.00288	CbGpPWpGaD
Ciclesonide—Headache—Etoposide—urinary bladder cancer	0.000854	0.00153	CcSEcCtD
Ciclesonide—Arthralgia—Methotrexate—urinary bladder cancer	0.000852	0.00153	CcSEcCtD
Ciclesonide—Chest pain—Methotrexate—urinary bladder cancer	0.000852	0.00153	CcSEcCtD
Ciclesonide—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000849	0.00152	CcSEcCtD
Ciclesonide—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000845	0.00284	CbGpPWpGaD
Ciclesonide—NR3C1—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.000842	0.00283	CbGpPWpGaD
Ciclesonide—Back pain—Doxorubicin—urinary bladder cancer	0.000838	0.00151	CcSEcCtD
Ciclesonide—Palpitations—Epirubicin—urinary bladder cancer	0.000828	0.00149	CcSEcCtD
Ciclesonide—NR3C1—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.000819	0.00275	CbGpPWpGaD
Ciclesonide—Cough—Epirubicin—urinary bladder cancer	0.000817	0.00147	CcSEcCtD
Ciclesonide—NR3C1—Circadian Clock—EP300—urinary bladder cancer	0.000817	0.00274	CbGpPWpGaD
Ciclesonide—Infection—Methotrexate—urinary bladder cancer	0.000811	0.00146	CcSEcCtD
Ciclesonide—Nausea—Etoposide—urinary bladder cancer	0.00081	0.00146	CcSEcCtD
Ciclesonide—Hypertension—Epirubicin—urinary bladder cancer	0.000809	0.00145	CcSEcCtD
Ciclesonide—Chest pain—Epirubicin—urinary bladder cancer	0.000797	0.00143	CcSEcCtD
Ciclesonide—Arthralgia—Epirubicin—urinary bladder cancer	0.000797	0.00143	CcSEcCtD
Ciclesonide—NR3C1—AP-1 transcription factor network—CXCL8—urinary bladder cancer	0.000786	0.00264	CbGpPWpGaD
Ciclesonide—NR3C1—Adipogenesis—FAS—urinary bladder cancer	0.000785	0.00264	CbGpPWpGaD
Ciclesonide—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000783	0.00263	CbGpPWpGaD
Ciclesonide—Dry mouth—Epirubicin—urinary bladder cancer	0.00078	0.0014	CcSEcCtD
Ciclesonide—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000772	0.00259	CbGpPWpGaD
Ciclesonide—Palpitations—Doxorubicin—urinary bladder cancer	0.000766	0.00138	CcSEcCtD
Ciclesonide—Infection—Epirubicin—urinary bladder cancer	0.000759	0.00136	CcSEcCtD
Ciclesonide—Cough—Doxorubicin—urinary bladder cancer	0.000756	0.00136	CcSEcCtD
Ciclesonide—NR3C1—AP-1 transcription factor network—IL2—urinary bladder cancer	0.000751	0.00252	CbGpPWpGaD
Ciclesonide—Hypertension—Doxorubicin—urinary bladder cancer	0.000748	0.00134	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000744	0.00134	CcSEcCtD
Ciclesonide—Chest pain—Doxorubicin—urinary bladder cancer	0.000738	0.00133	CcSEcCtD
Ciclesonide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000738	0.00133	CcSEcCtD
Ciclesonide—NR3C1—AP-1 transcription factor network—CCND1—urinary bladder cancer	0.000732	0.00246	CbGpPWpGaD
Ciclesonide—Dyspnoea—Methotrexate—urinary bladder cancer	0.000728	0.00131	CcSEcCtD
Ciclesonide—Dry mouth—Doxorubicin—urinary bladder cancer	0.000722	0.0013	CcSEcCtD
Ciclesonide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000719	0.00129	CcSEcCtD
Ciclesonide—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000718	0.00241	CbGpPWpGaD
Ciclesonide—NR3C1—AP-1 transcription factor network—MMP9—urinary bladder cancer	0.000711	0.00239	CbGpPWpGaD
Ciclesonide—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000708	0.00238	CbGpPWpGaD
Ciclesonide—NR3C1—AP-1 transcription factor network—PTEN—urinary bladder cancer	0.000707	0.00237	CbGpPWpGaD
Ciclesonide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000705	0.00127	CcSEcCtD
Ciclesonide—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000705	0.00237	CbGpPWpGaD
Ciclesonide—Fatigue—Methotrexate—urinary bladder cancer	0.000704	0.00127	CcSEcCtD
Ciclesonide—Infection—Doxorubicin—urinary bladder cancer	0.000703	0.00126	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000696	0.00125	CcSEcCtD
Ciclesonide—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000695	0.00234	CbGpPWpGaD
Ciclesonide—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—urinary bladder cancer	0.000692	0.00233	CbGpPWpGaD
Ciclesonide—Dyspnoea—Epirubicin—urinary bladder cancer	0.000682	0.00122	CcSEcCtD
Ciclesonide—NR3C1—AP-1 transcription factor network—EP300—urinary bladder cancer	0.000674	0.00226	CbGpPWpGaD
Ciclesonide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000673	0.00121	CcSEcCtD
Ciclesonide—NR3C1—Glucocorticoid receptor regulatory network—IL2—urinary bladder cancer	0.000662	0.00222	CbGpPWpGaD
Ciclesonide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00066	0.00119	CcSEcCtD
Ciclesonide—Fatigue—Epirubicin—urinary bladder cancer	0.000659	0.00118	CcSEcCtD
Ciclesonide—Urticaria—Methotrexate—urinary bladder cancer	0.000649	0.00117	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000644	0.00116	CcSEcCtD
Ciclesonide—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000631	0.00113	CcSEcCtD
Ciclesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	0.00063	0.00212	CbGpPWpGaD
Ciclesonide—NR3C1—Adipogenesis—PPARG—urinary bladder cancer	0.000628	0.00211	CbGpPWpGaD
Ciclesonide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—urinary bladder cancer	0.000624	0.0021	CbGpPWpGaD
Ciclesonide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000623	0.00112	CcSEcCtD
Ciclesonide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000611	0.0011	CcSEcCtD
Ciclesonide—Fatigue—Doxorubicin—urinary bladder cancer	0.00061	0.0011	CcSEcCtD
Ciclesonide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000607	0.00204	CbGpPWpGaD
Ciclesonide—Urticaria—Epirubicin—urinary bladder cancer	0.000607	0.00109	CcSEcCtD
Ciclesonide—NR3C1—Adipogenesis—RB1—urinary bladder cancer	0.000601	0.00202	CbGpPWpGaD
Ciclesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	0.0006	0.00201	CbGpPWpGaD
Ciclesonide—NR3C1—Adipogenesis—IGF1—urinary bladder cancer	0.000595	0.002	CbGpPWpGaD
Ciclesonide—NR3C1—Glucocorticoid receptor regulatory network—EP300—urinary bladder cancer	0.000594	0.00199	CbGpPWpGaD
Ciclesonide—NR3C1—AP-1 transcription factor network—MYC—urinary bladder cancer	0.000587	0.00197	CbGpPWpGaD
Ciclesonide—Asthenia—Methotrexate—urinary bladder cancer	0.000586	0.00105	CcSEcCtD
Ciclesonide—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000574	0.00193	CbGpPWpGaD
Ciclesonide—Urticaria—Doxorubicin—urinary bladder cancer	0.000562	0.00101	CcSEcCtD
Ciclesonide—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000556	0.00187	CbGpPWpGaD
Ciclesonide—Asthenia—Epirubicin—urinary bladder cancer	0.000548	0.000985	CcSEcCtD
Ciclesonide—Dizziness—Methotrexate—urinary bladder cancer	0.00054	0.00097	CcSEcCtD
Ciclesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	0.000523	0.00175	CbGpPWpGaD
Ciclesonide—NR3C1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000521	0.00175	CbGpPWpGaD
Ciclesonide—Rash—Methotrexate—urinary bladder cancer	0.000515	0.000925	CcSEcCtD
Ciclesonide—Dermatitis—Methotrexate—urinary bladder cancer	0.000515	0.000924	CcSEcCtD
Ciclesonide—Headache—Methotrexate—urinary bladder cancer	0.000512	0.000919	CcSEcCtD
Ciclesonide—Asthenia—Doxorubicin—urinary bladder cancer	0.000507	0.000912	CcSEcCtD
Ciclesonide—Dizziness—Epirubicin—urinary bladder cancer	0.000505	0.000908	CcSEcCtD
Ciclesonide—Nausea—Methotrexate—urinary bladder cancer	0.000485	0.000872	CcSEcCtD
Ciclesonide—NR3C1—AP-1 transcription factor network—TP53—urinary bladder cancer	0.000482	0.00162	CbGpPWpGaD
Ciclesonide—Rash—Epirubicin—urinary bladder cancer	0.000482	0.000866	CcSEcCtD
Ciclesonide—Dermatitis—Epirubicin—urinary bladder cancer	0.000482	0.000865	CcSEcCtD
Ciclesonide—Headache—Epirubicin—urinary bladder cancer	0.000479	0.00086	CcSEcCtD
Ciclesonide—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000469	0.00158	CbGpPWpGaD
Ciclesonide—Dizziness—Doxorubicin—urinary bladder cancer	0.000468	0.00084	CcSEcCtD
Ciclesonide—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000463	0.00155	CbGpPWpGaD
Ciclesonide—Nausea—Epirubicin—urinary bladder cancer	0.000454	0.000816	CcSEcCtD
Ciclesonide—Rash—Doxorubicin—urinary bladder cancer	0.000446	0.000801	CcSEcCtD
Ciclesonide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000446	0.0008	CcSEcCtD
Ciclesonide—Headache—Doxorubicin—urinary bladder cancer	0.000443	0.000796	CcSEcCtD
Ciclesonide—NR3C1—Adipogenesis—CDKN1A—urinary bladder cancer	0.000432	0.00145	CbGpPWpGaD
Ciclesonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	0.000425	0.00143	CbGpPWpGaD
Ciclesonide—Nausea—Doxorubicin—urinary bladder cancer	0.00042	0.000755	CcSEcCtD
Ciclesonide—NR3C1—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000414	0.00139	CbGpPWpGaD
Ciclesonide—NR3C1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000414	0.00139	CbGpPWpGaD
Ciclesonide—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000386	0.0013	CbGpPWpGaD
Ciclesonide—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00038	0.00128	CbGpPWpGaD
Ciclesonide—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000375	0.00126	CbGpPWpGaD
Ciclesonide—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000364	0.00122	CbGpPWpGaD
Ciclesonide—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000355	0.00119	CbGpPWpGaD
Ciclesonide—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000354	0.00119	CbGpPWpGaD
Ciclesonide—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00035	0.00117	CbGpPWpGaD
Ciclesonide—NR3C1—Adipogenesis—TNF—urinary bladder cancer	0.000333	0.00112	CbGpPWpGaD
Ciclesonide—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.00032	0.00107	CbGpPWpGaD
Ciclesonide—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000288	0.000968	CbGpPWpGaD
Ciclesonide—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000252	0.000847	CbGpPWpGaD
Ciclesonide—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000251	0.000844	CbGpPWpGaD
Ciclesonide—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000249	0.000835	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000236	0.000793	CbGpPWpGaD
Ciclesonide—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000232	0.000778	CbGpPWpGaD
Ciclesonide—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000229	0.00077	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	0.000229	0.000768	CbGpPWpGaD
Ciclesonide—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000229	0.000768	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000224	0.000752	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000224	0.000752	CbGpPWpGaD
Ciclesonide—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.00022	0.000739	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	0.000205	0.000688	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—ESR2—urinary bladder cancer	0.000199	0.00067	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	0.000184	0.000619	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	0.000174	0.000585	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	0.00017	0.00057	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	0.000154	0.000519	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	0.000154	0.000517	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	0.000146	0.000492	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	0.000146	0.000492	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	0.000145	0.000486	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—TYMP—urinary bladder cancer	0.000136	0.000456	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	0.000134	0.00045	CbGpPWpGaD
Ciclesonide—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000131	0.000439	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—NAT2—urinary bladder cancer	0.000123	0.000412	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—ESR1—urinary bladder cancer	0.000121	0.000406	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	0.000121	0.000405	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	0.000114	0.000382	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	0.000111	0.000373	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—PPARG—urinary bladder cancer	0.00011	0.000371	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	0.000106	0.000356	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—RRM2—urinary bladder cancer	0.000106	0.000356	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	9.81e-05	0.000329	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—ENO2—urinary bladder cancer	9.81e-05	0.000329	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	9.52e-05	0.00032	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	8.87e-05	0.000298	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	8.02e-05	0.000269	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—NQO1—urinary bladder cancer	7.91e-05	0.000266	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	6.93e-05	0.000233	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	6.6e-05	0.000222	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	6.41e-05	0.000215	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	6.41e-05	0.000215	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—MYC—urinary bladder cancer	6.29e-05	0.000211	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	6.22e-05	0.000209	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—TYMS—urinary bladder cancer	6.13e-05	0.000206	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	6.06e-05	0.000204	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	6.06e-05	0.000204	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—GPX1—urinary bladder cancer	5.8e-05	0.000195	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	5.7e-05	0.000191	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	5.36e-05	0.00018	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.17e-05	0.000174	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—PPARG—urinary bladder cancer	4.34e-05	0.000146	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.31e-05	0.000145	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	4.17e-05	0.00014	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.01e-05	0.000135	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.96e-05	0.000133	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.96e-05	0.000133	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.8e-05	0.000127	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.73e-05	0.000125	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.5e-05	0.000118	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.42e-05	0.000115	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.98e-05	0.0001	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.84e-05	9.54e-05	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.84e-05	9.54e-05	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.73e-05	9.16e-05	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.23e-05	7.5e-05	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.95e-05	6.54e-05	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.86e-05	6.24e-05	CbGpPWpGaD
